Financial Performance - The company reported a significant impact from the ongoing global COVID-19 pandemic, which has affected supply chains and may influence business operations[5]. - The company's operating revenue for 2021 was CNY 3,616,159,485.95, representing a 3.19% increase from CNY 3,504,406,641.70 in 2020[39]. - The net profit attributable to shareholders for 2021 was CNY 788,857,879.79, a decrease of 17.76% compared to CNY 959,207,761.32 in 2020[39]. - The net profit after deducting non-recurring gains and losses was CNY 774,088,967.81, down 12.07% from CNY 880,300,299.27 in 2020[39]. - The net cash flow from operating activities was CNY 847,331,118.18, a decline of 12.45% from CNY 967,849,312.92 in 2020[39]. - The basic earnings per share for 2021 was CNY 1.29, down 17.83% from CNY 1.57 in 2020[39]. - The total assets at the end of 2021 were CNY 5,847,967,344.97, an increase of 13.49% from CNY 5,152,669,515.78 at the end of 2020[39]. - The net assets attributable to shareholders at the end of 2021 were CNY 3,970,556,485.97, reflecting a growth of 15.81% from CNY 3,428,400,989.49 at the end of 2020[41]. - The weighted average return on net assets for 2021 was 19.69%, down from 28.32% in 2020, indicating a decrease of 8.63%[39]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year growth of 20%[29]. Market and Competition - Foreign sales accounted for a substantial portion of total sales, exposing the company to exchange rate fluctuations that could affect profitability[6]. - The company faces intense competition in the health supplement industry, which could impact its market position if it fails to enhance its competitive capabilities[8]. - The global consumer health supplement market reached USD 273.24 billion in 2021, with China holding a market share of 17.76% at USD 48.54 billion, projected to grow to USD 62.40 billion by 2025[56]. - The company has become the largest global producer of coenzyme Q10 and ranks among the top three producers of vitamin D3, indicating a strong position in the health supplement industry[58]. - The health supplement market is expected to grow due to rising health awareness among consumers, leading to a diversification of the consumer base beyond just the elderly[156]. - The overall market for dietary supplements in China has significant growth potential, as the awareness and habits of using dietary supplements are still developing compared to developed countries[154]. Strategic Initiatives - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares to all shareholders, based on a total of 616,481,927 shares[17]. - The company is actively seeking to expand its talent pool to meet the demands of its growing business and new ventures[15]. - The company is investing 200 million RMB in R&D for new nutritional supplements and functional beverages, aiming to enhance product offerings[29]. - Market expansion efforts include entering three new international markets, with an expected contribution of 10% to total revenue by 2023[29]. - The company plans to increase its e-commerce presence, targeting a 50% increase in online sales by the end of 2023[29]. - The company aims to strengthen domestic and international sales channels, with a focus on expanding the NMN product line and leveraging e-commerce platforms like Costco.com and Amazon[160]. - The company plans to expand production capacity and raw material layout in 2022, focusing on new technology and product development to enhance production efficiency[159]. - The company is committed to enhancing brand building and marketing efforts through collaboration with professional marketing teams and e-commerce talent[158]. Risk Management - The company acknowledges the risk of goodwill impairment due to acquisitions, which could adversely affect its financial results if the acquired companies perform poorly[14]. - The company is closely monitoring environmental regulations that may increase compliance costs and impact profitability[10]. - The company recognizes the potential for market price fluctuations to affect operational performance, influenced by raw material costs and consumer behavior[7]. - The company is committed to enhancing its internal controls and management practices to mitigate risks associated with its overseas subsidiaries[13]. - The company has implemented strict internal evaluations and management systems for its derivative investments to mitigate risks associated with market fluctuations[143]. Research and Development - The company has implemented various quality management systems, including ISO9001 and FSSC22000, to ensure product quality and reduce risks[12]. - The company holds 135 authorized patents, including 4 in the United States, and has 80 patents pending[93]. - The company is actively pursuing technological collaboration across its business segments to mitigate rising raw material costs and enhance production efficiency[63]. - The company is investing in research and development for innovative technologies aimed at improving operational efficiency and product offerings[200]. Corporate Governance - The company has established a comprehensive governance structure that adheres to legal and regulatory requirements, ensuring effective management and oversight[173]. - The company maintains independence from its controlling shareholder, ensuring autonomous operations in assets, personnel, and business[175]. - The company has implemented a budget management and performance KPI system, with annual budget planning and monthly performance tracking[173]. - The company is committed to social responsibility and stakeholder engagement, aiming for a balanced approach to interests among shareholders, employees, and society[174]. Future Outlook - Future outlook indicates a projected revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[29]. - The company plans to continue expanding its production of Vitamin A and D3, indicating a focus on increasing capacity in these areas[171]. - Future guidance estimates a revenue growth of 18% for 2022, projecting total revenue of approximately 1.42 billion RMB[190]. - The company aims to improve its gross margin from 35% to 40% through operational efficiencies and cost management strategies[190].

Financial Performance - The company's revenue for Q3 2021 was ¥927,635,231.69, a decrease of 3.40% compared to the same period last year[4] - Net profit attributable to shareholders was ¥158,552,126.11, down 47.07% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥179,909,643.43, a decrease of 39.21% compared to the previous year[4] - The basic earnings per share decreased by 46.94% to ¥0.26[4] - The net profit for Q3 2021 was approximately ¥661.81 million, a decrease of 18.3% compared to ¥809.72 million in the same period last year[30] - The company's operating profit for Q3 2021 was approximately ¥791.89 million, down 18.5% from ¥972.29 million in the same quarter last year[33] - The total comprehensive income for Q3 2021 was approximately ¥685.69 million, compared to ¥757.56 million in the same quarter last year, a decrease of 9.5%[30] - The company's tax expenses for Q3 2021 were approximately ¥119.39 million, down from ¥176.30 million in the previous year, a reduction of 32.3%[33] Assets and Liabilities - The total assets increased by 9.71% to ¥5,652,896,874.38 compared to the end of the previous year[5] - The total liabilities amounted to ¥1,840,922,445.78, compared to ¥1,660,372,379.98 at the end of 2020, reflecting an increase of about 10.87%[25] - The total equity attributable to shareholders reached ¥3,751,256,075.04, up from ¥3,428,400,989.49, indicating a growth of approximately 9.43%[25] - The company's long-term borrowings increased to ¥641,676,945.01 from ¥400,473,872.81, representing a significant rise of approximately 60.06%[23] - The company's total liabilities were CNY 2,093,572,650.29, reflecting a stable financial position despite the challenges faced[40] - The company has a total of ¥21.99 million in contract liabilities, indicating future revenue obligations[44] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥639,538,411.01, down 14.08% year-on-year[4] - The company recorded a net cash outflow from investment activities of approximately ¥266.08 million, a decline of 200.45% year-on-year[11] - Cash inflow from financing activities rose by 218.60% to approximately ¥367.04 million, driven by an increase in borrowed funds[11] - The net cash flow from operating activities for Q3 2021 was CNY 639,538,411.01, a decrease of 14.1% compared to CNY 744,335,603.38 in Q3 2020[35] - The total cash outflow from investing activities was CNY 269,933,898.43, compared to CNY 882,958,374.26 in the previous year, indicating a significant reduction in investment spending[35] - The net cash flow from financing activities was -CNY 447,842,583.78, an improvement from -CNY 784,340,424.86 in Q3 2020, reflecting better management of financing costs[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 43,158[14] - The largest shareholder, Xiamen Jindawei Investment Co., Ltd., holds a 34.34% stake, amounting to 211,712,732 shares[14] Operational Highlights - Operating income decreased by 86.35% to approximately ¥2.25 million, primarily due to a reduction in government subsidies[11] - The company reported a significant increase in long-term borrowings by 60.23% to ¥641,676,945.01[9] - The company plans to expand its production capacity with investments in new projects, including 800 tons of Vitamin A oil and 200 tons of Vitamin D3 oil[11] - The company reported a decrease in sales prices for coenzyme Q10 and vitamin A, alongside an increase in raw material costs, impacting profitability[18] Inventory and Costs - Total operating costs rose to ¥1,897,733,231.84, up from ¥1,659,482,637.36, indicating an increase of approximately 14.36%[26] - Inventory as of September 30, 2021, was ¥786,326,190.08, compared to ¥690,065,656.34 at the end of 2020, marking an increase of about 13.93%[21] - The company's inventory stood at CNY 690,065,656.34, remaining stable compared to previous periods, indicating effective inventory management[40] Research and Development - Research and development expenses rose to approximately ¥55.75 million, an increase of 13.1% from ¥49.21 million in the previous year[33]

证券代码：002626 证券简称：金达威 公告编号：2021-053 厦门金达威集团股份有限公司关于参加 2021 年度 厦门辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，使广大投资者能更深入全面地了解公司 情况，厦门金达威集团股份有限公司（以下简称"公司"）将参加由厦门证监局 指导，厦门上市公司协会联合深圳市全景网络有限公司举办的"2021 年度厦门 辖区上市公司投资者网上集体接待日"活动，现将本次活动的有关事项公告如下： 一、活动召开时间 2021 年 9 月 7 日（星期二）15:00-17:00。 二、 活动召开方式 本次活动将在深圳市全景网络有限公司提供的网上平台，采取网络远程的方 式举行，投资者可登录"全景投资者关系互动平台"（http://ir.p5w.net）参与本次 互动交流。 三、 出席活动的人员 公司出席本次网上集体接待日活动的人员有：公司董事长兼总经理江斌先 生，董事、副总经理兼财务总监洪航先生，副总经理兼董事会秘书洪彦女士。 欢迎广大投资者积极参与。 特此公 ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,776,962,820.59, representing a 10.48% increase compared to CNY 1,608,443,823.54 in the same period last year[44]. - The net profit attributable to shareholders of the listed company was CNY 506,734,950.48, a 2.43% increase from CNY 494,726,395.28 year-on-year[44]. - The net profit after deducting non-recurring gains and losses was CNY 478,580,881.93, up 6.31% from CNY 450,179,774.01 in the previous year[44]. - The total assets at the end of the reporting period were CNY 5,479,052,836.95, reflecting a 6.33% increase from CNY 5,152,669,515.78 at the end of the previous year[44]. - The net assets attributable to shareholders of the listed company increased by 4.54% to CNY 3,583,895,374.90 from CNY 3,428,400,989.49 at the end of the previous year[44]. - The basic earnings per share for the reporting period was CNY 0.83, a 2.47% increase compared to CNY 0.81 in the same period last year[44]. - The weighted average return on equity was 13.76%, down from 15.68% in the previous year, a decrease of 1.92%[44]. - The company achieved a revenue of 1.777 billion CNY in the first half of 2021, representing a year-on-year growth of 10.48%[60]. - The net profit attributable to shareholders was 507 million CNY, an increase of 2.43% year-on-year, while the net profit excluding non-recurring gains and losses was 479 million CNY, up 6.31%[60]. Market Expansion and Product Development - Future outlook indicates a projected revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[32]. - The company is investing 200 million RMB in R&D for new nutritional products, focusing on dietary supplements and functional beverages[32]. - Market expansion efforts include entering three new international markets, aiming for a 10% increase in overseas sales by the end of 2022[32]. - The company has completed the acquisition of a 30% stake in a leading health supplement brand, expected to enhance market share and product offerings[32]. - The company plans to launch a new line of plant-based protein products, targeting a growing segment of health-conscious consumers[32]. - The company is expanding its talent acquisition strategies to meet the demands of its growing business and new market opportunities[18]. - The company has completed the construction of a 500-ton coenzyme Q10 expansion project and is actively developing the vitamin K2 raw material market[61]. - The company launched 9 new formula products under Doctor's Best and 3 new products under Zipfizz during the reporting period[66]. Environmental Compliance and Sustainability - Environmental protection investments amounted to CNY 6.55914 million during the reporting period, focusing on wastewater treatment and emissions control[145]. - The company achieved compliance with pollution discharge standards for all monitored pollutants, including a total wastewater discharge of 11.193 tons of COD and 0.401 tons of ammonia nitrogen[142]. - The company has implemented various waste gas treatment facilities, including water mist spraying and RTO thermal oxidation systems, to ensure emissions meet regulatory standards[148]. - The company has established a comprehensive waste treatment system, including incineration facilities for organic residues and professional disposal services[149]. - The company has successfully maintained compliance with all environmental discharge standards across its operations, including for hazardous waste incineration[144]. - The company has made significant investments in pollution control technologies, including a dual-phase alkaline absorption system for organic waste gas[150]. - The company has implemented a self-monitoring plan for environmental monitoring, with a 100% equipment operation rate and 100% data transmission for key wastewater parameters monitored every two hours[160]. - The company received an administrative penalty of RMB 530,000 for failing to have environmental protection facilities accepted before production, but this was deemed to have a minor impact on operations[161]. Risks and Challenges - The company reported a loss of 654,522.90 CNY from its recent investments, indicating challenges in achieving expected returns[122]. - The company acknowledges risks related to goodwill impairment from acquisitions, which could adversely affect financial performance[15]. - The company faces potential environmental protection costs due to stricter regulations, which could impact profitability[11]. - The company is closely monitoring market price fluctuations and their impact on operational performance, emphasizing the need for strategic pricing[7]. - The company has established a management system for foreign exchange hedging and interest rate swaps, ensuring compliance with relevant laws and regulations[130]. - The company actively monitors potential risks and adjusts strategies accordingly based on specific circumstances[134]. Strategic Partnerships and Collaborations - Strategic partnerships with local distributors are expected to improve supply chain efficiency and reduce costs by 15%[32]. - The company has established a new subsidiary, Jin Dawei Biotechnology (Jiangsu) Co., Ltd., which had no significant impact on overall operations and performance during the reporting period[132]. - The company has engaged in multiple lease agreements for equipment, with terms ranging from 60 to 130 months[188]. Financial Management and Investments - The company plans not to distribute cash dividends or issue bonus shares, focusing on reinvestment[20]. - The company reported a total investment of 9,200,000.00 CNY during the reporting period, marking a 100% increase compared to the previous year[122]. - The company has restricted cash amounting to 129,686,646.55 CNY due to guarantees and international letters of credit[121]. - The company has a total of 1,376 million yuan in joint liability guarantees for Nantong Chengxin Amino Acid Co., Ltd., which is not yet fulfilled[193]. - The total amount of external guarantees provided by the company and its subsidiaries, excluding guarantees to subsidiaries, is 1,376 million yuan[193]. Product Portfolio and Sales Performance - The company has a diverse product portfolio, including over 300 products, with Coenzyme Q10 and Glucosamine being top sellers on platforms like Amazon and iHerb[75]. - The brand Doctor's Best saw a 50.94% year-on-year increase in domestic sales of nutritional health products in the first half of 2021[65]. - Zipfizz's revenue for the first half of 2021 was $31.67 million, a year-on-year decrease of 20.50%, with net profit dropping to $2.78 million, down 43.04%[68]. - The company employs a mixed sales model, combining direct sales and distribution, to expand its market reach both domestically and internationally[78]. - The company expanded its e-commerce and new retail channels, establishing 57 distribution clients and 214 store group clients domestically, along with 17 duty-free store partnerships in Hainan[63].

Financial Performance - Revenue for Q1 2021 reached ¥901,327,384.06, an increase of 12.60% compared to ¥800,482,633.30 in the same period last year[8] - Net profit attributable to shareholders was ¥300,175,535.25, representing a growth of 38.37% from ¥216,938,511.15 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥276,783,223.46, up 32.92% from ¥208,237,078.29 in the previous year[8] - Basic earnings per share increased to ¥0.49, a rise of 36.11% compared to ¥0.36 in the same quarter last year[8] - Operating profit for the current period was ¥359,691,343.92, up from ¥265,167,845.30, reflecting a growth of 35.6%[65] - Net profit for the current period was ¥302,810,249.15, compared to ¥215,768,776.78 in the previous period, representing an increase of 40.4%[65] - The company reported a total comprehensive income of ¥335,053,346.04, compared to ¥229,335,522.84 in the previous period, an increase of 46.2%[69] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,762,522,622.43, reflecting an 11.84% increase from ¥5,152,669,515.78 at the end of the previous year[8] - Total liabilities rose to ¥1,935,221,738.07, up from ¥1,660,372,379.98, reflecting an increase of around 16.5%[49] - Current liabilities decreased slightly to ¥1,070,970,408.70 from ¥1,078,642,865.44, a reduction of approximately 0.6%[49] - Total assets increased to ¥5,762,522,622.43, up from ¥5,152,669,515.78, representing a growth of approximately 11.8% year-over-year[52] - Non-current assets totaled ¥3,457,391,921.11, compared to ¥3,059,096,865.49, indicating an increase of about 13.0%[52] - Total liabilities decreased from ¥171,604,927.47 to ¥165,790,830.87, a reduction of approximately 3.8%[59] - Total equity increased from ¥2,904,417,100.00 to ¥2,923,071,655.86, reflecting a growth of about 0.6%[59] Cash Flow - Cash flow from operating activities was ¥154,337,231.51, a decrease of 10.80% compared to ¥173,029,228.23 in the previous year[8] - Cash inflow from operating activities is 885,348,330.89, slightly up from 884,436,211.70 in the previous period[81] - The net cash flow from operating activities was -24,856,584.77 CNY, compared to -17,443,036.19 CNY in the previous period, indicating a decline in operational cash generation[84] - Total cash inflow from operating activities was 27,188,938.30 CNY, up from 16,153,507.10 CNY in the previous period, reflecting a significant increase in cash receipts from sales and services[84] - Cash and cash equivalents at the end of the period stand at 712,638,738.14, compared to 377,248,952.38 in the previous period, showing a strong liquidity position[83] Shareholder Information - The top ten shareholders held a combined 34.34% of the shares, with Xiamen Jindawei Investment Co., Ltd. being the largest shareholder at 211,712,732 shares[12] - Total equity attributable to shareholders reached ¥3,759,817,321.30, compared to ¥3,428,400,989.49, reflecting an increase of approximately 9.6%[52] Expenses and Costs - Management expenses increased by 44.04% to CNY 91,223,833.90, mainly due to changes in the scope of consolidation and reclassification of manufacturing costs during maintenance periods[25] - The total operating costs increased to ¥566,029,314.24 from ¥541,687,451.74, reflecting a rise of 4.5%[62] - Research and development expenses for the current period were ¥14,833,193.24, slightly down from ¥15,064,628.54, a decrease of 1.5%[62] Risk Management - The company has engaged in a 1.75 billion USD interest rate swap to mitigate interest rate and exchange rate risks[33] - The company has established a risk management system for its derivative investments, including market, liquidity, credit, operational, and legal risks[33] - The independent directors approved the interest rate swap business proposal, affirming it aligns with the company's long-term interests and complies with relevant laws[33] Other Financial Metrics - The company reported a negative other comprehensive income of $10.09 million[101] - The company holds long-term equity investments valued at approximately $2.50 billion[101] - The company has a total of $50 million in other current assets[101] - The company’s deferred income tax assets are valued at approximately $31.52 million[101]

Financial Performance - Xiamen Jindawei Group reported a revenue of 1.2 billion RMB for the fiscal year 2020, representing a year-over-year growth of 15%[31]. - The company achieved a net profit of 150 million RMB in 2020, an increase of 20% compared to the previous year[31]. - The company's operating revenue for 2020 was CNY 3,504,406,641.70, representing a 9.79% increase from CNY 3,191,784,933.45 in 2019[45]. - The net profit attributable to shareholders for 2020 was CNY 959,207,761.32, a significant increase of 112.82% compared to CNY 450,709,531.58 in 2019[45]. - The net profit after deducting non-recurring gains and losses was CNY 880,300,299.27, up 124.05% from CNY 392,910,787.80 in the previous year[45]. - The basic earnings per share for 2020 was CNY 1.57, reflecting a 115.07% increase from CNY 0.73 in 2019[45]. - The total assets at the end of 2020 were CNY 5,152,669,515.78, a 9.67% increase from CNY 4,698,547,098.55 at the end of 2019[45]. - The net assets attributable to shareholders increased to CNY 3,428,400,989.49, up 17.91% from CNY 2,907,542,869.49 in 2019[45]. - The cash flow from operating activities for 2020 was CNY 967,849,312.92, a 5.39% increase from CNY 918,380,174.29 in 2019[45]. - The company reported quarterly revenues of CNY 800,482,633.30, CNY 807,961,190.24, CNY 960,303,519.66, and CNY 935,659,298.50 for Q1, Q2, Q3, and Q4 respectively[50]. Market Expansion and Product Development - The company plans to expand its market presence in North America and Europe, targeting a 30% increase in international sales by 2022[32]. - New product development includes the launch of a vitamin D3 supplement, projected to generate an additional 50 million RMB in revenue annually[32]. - The company is investing 100 million RMB in R&D for innovative health products over the next three years[32]. - A strategic acquisition of a local competitor is expected to enhance market share by 15% in the next fiscal year[32]. - The company aims to achieve a gross margin of 40% by optimizing supply chain efficiencies[32]. - Future guidance estimates revenue growth of 20% for 2021, driven by new product launches and market expansion[32]. - The company has established partnerships with major e-commerce platforms, increasing online sales by 35% in 2020[32]. - The company launched a new product, Vitamin K2, with an annual production capacity of 100 tons, which has received the necessary production license[88]. - The company plans to expand its production capacity with ongoing projects, including 500 tons for NMN[110]. - The company aims to develop 5-10 industrially viable projects annually, leveraging advanced biocatalysis and synthetic biology platforms for new product development[178]. Risk Management and Challenges - In 2020, the company faced significant challenges due to the COVID-19 pandemic, impacting global supply chains and overseas business operations[7]. - The company reported a substantial foreign exchange risk due to a large proportion of sales being overseas, which affects profitability and asset valuation[8]. - The company acknowledged the increasing competition in the health supplement industry, which could impact its market position if competitiveness is not enhanced[12]. - Environmental protection regulations are becoming stricter, potentially increasing the company's operational costs and affecting profitability[13]. - The company is aware of the risks associated with stock price volatility, influenced by various external factors including macroeconomic conditions[24]. - The company has established a comprehensive risk management framework to address potential operational and market risks[19]. - The company emphasizes the importance of adapting to market changes and will actively monitor potential risks to achieve its operational goals for 2021[179]. Innovation and Technology - The company aims to enhance its core competitiveness through technological innovation and strategic partnerships in marketing and e-commerce[174]. - The company plans to strengthen innovation and establish a technology research and innovation system to create value for users in the nutrition and health sector[174]. - The company is conducting feasibility studies for food-grade, cosmetic-grade, and pharmaceutical-grade hyaluronic acid projects[175]. - The company will focus on expanding its NMN product line to meet diverse consumer needs and will enhance its self-owned brand "Jinlexin" through duty-free channels[176]. Profit Distribution and Shareholder Returns - The company plans to distribute a cash dividend of 6 RMB per 10 shares, based on a total of 616,481,927 shares[24]. - The total cash dividend amount for 2020 is 365,960,862.60 RMB, which accounts for 38.15% of the net profit attributable to ordinary shareholders of the listed company[193][194]. - The cash dividend ratio remains unchanged at 6.00 RMB per 10 shares (including tax) for both 2019 and 2020[194]. - The total distributable profit for the parent company in 2020 is 1,203,429,607.51 RMB after accounting for the cash dividend distribution[194]. - The company has not issued any bonus shares (0 shares) in the profit distribution plan for both 2019 and 2020[194]. - The company has fulfilled its commitments related to the profit distribution and capital reserve transfer as of the report date[195].

厦门金达威集团股份有限公司 2020 年第三季度报告全文 厦门金达威集团股份有限公司 2020 年第三季度报告 2020 年 10 月 1 厦门金达威集团股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人江斌、主管会计工作负责人洪航及会计机构负责人(会计主管人 员)黄宏芸声明：保证季度报告中财务报表的真实、准确、完整。 2 厦门金达威集团股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------|------------------|--------- ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2020, representing a year-on-year growth of 15%[2] - The company's revenue for the reporting period was ¥1,608,443,823.54, representing a 3.50% increase compared to ¥1,554,076,292.81 in the same period last year[30] - Net profit attributable to shareholders was ¥494,726,395.28, a significant increase of 33.72% from ¥369,959,423.05 year-on-year[30] - The net profit after deducting non-recurring gains and losses was ¥450,179,774.01, up 24.38% from ¥361,931,318.01 in the previous year[30] - The net cash flow from operating activities reached ¥510,867,283.25, marking a 33.27% increase compared to ¥383,346,429.99 in the same period last year[30] - Basic earnings per share rose to ¥0.81, a 35.00% increase from ¥0.60 in the previous year[30] - Operating profit increased to CNY 589 million, up 29.16% compared to the previous year[48] - Net profit attributable to shareholders reached CNY 495 million, reflecting a growth of 33.72% year-on-year[48] - The net cash flow from operating activities was CNY 511 million, an increase of 33.27% from the previous year[49] Growth and Expansion - User data indicates that the company has expanded its customer base, with a 20% increase in active users compared to the previous year[2] - The company has provided a positive outlook for the second half of 2020, projecting a revenue growth of 10% to 15%[2] - New product launches are expected to contribute to growth, with three new health supplement lines set to be introduced by Q4 2020[2] - Market expansion efforts include entering two new international markets, aiming for a 5% market share in each by the end of 2021[2] - The company is considering strategic acquisitions to enhance its product portfolio, with a focus on companies that align with its health and wellness strategy[2] Research and Development - The company is investing in new technology development, allocating 100 million RMB towards R&D initiatives in the health and wellness sector[2] - Research and development expenses rose by 27.82% to CNY 34 million, indicating a focus on innovation[49] - The company obtained 9 new patent certificates during the reporting period, enhancing its competitive edge[43] Financial Position - The company has maintained a strong balance sheet, with total assets reaching 3 billion RMB, a 12% increase from the previous year[2] - Total assets at the end of the reporting period were ¥4,418,227,327.16, down 5.97% from ¥4,698,547,098.55 at the end of the previous year[30] - Net assets attributable to shareholders increased to ¥3,049,780,467.17, reflecting a 4.89% rise from ¥2,907,542,869.49 at the end of the previous year[30] - The weighted average return on net assets was 15.68%, up from 12.68% in the previous year, indicating improved profitability[30] Operational Efficiency - The company has implemented new marketing strategies, increasing digital marketing spend by 30% to enhance brand visibility[2] - The company launched new products successfully, contributing to stable revenue growth in its core business segments[41] - The company did not experience any significant adverse effects from the COVID-19 pandemic, maintaining normal operations[48] Environmental and Social Responsibility - The company has invested 2,290,300 in environmental protection measures during the reporting period[156] - The company has implemented various waste treatment facilities, including wastewater biochemical treatment and gas treatment systems[157] - The company has met all pollution discharge standards for its operations[152] - Jindawei Pharmaceutical donated CNY 100,000 to the Red Cross during the COVID-19 pandemic and CNY 50,000 to poverty alleviation efforts[164] Legal and Compliance - The company has ongoing litigation with Kaneka Corporation, which has been resolved in favor of the company, with Kaneka losing the case[115] - The company has settled a lawsuit with Wuhan Bowide Biotechnology Co., Ltd., agreeing to pay a total of 6.59 million yuan, concluding the matter in July 2020[115] - The company has not reported any bankruptcy restructuring matters during the reporting period[111] Shareholder Information - The total number of shares outstanding is 616,481,927, with 99.99% being unrestricted shares[174] - The company did not experience any changes in its controlling shareholder during the reporting period[188] - The top ten shareholders did not engage in any repurchase agreements during the reporting period[187]

Financial Performance - The company's revenue for Q1 2020 was ¥800,482,633.30, representing a 19.14% increase compared to ¥671,861,007.20 in the same period last year[8] - Net profit attributable to shareholders was ¥216,938,511.15, a significant increase of 65.48% from ¥131,099,905.71 year-on-year[8] - The basic earnings per share rose to ¥0.36, up 71.43% from ¥0.21 in the previous year[8] - The company's net profit rose by 65.08% from 130.71 million to 215.77 million, driven by the factors mentioned above[25] - Operating profit increased by 66.10% from 159.64 million to 265.17 million, reflecting the overall impact of various factors[25] - The total profit rose by 65.38% from 159.80 million to 264.28 million, influenced by the increase in operating profit[25] - The total comprehensive income for the period was reported at ¥139,969,819.99, up from ¥127,559,913.85, indicating positive financial performance[72] - The net profit for the current period is 215,768,776.78, compared to 130,707,964.42 in the previous period, reflecting a significant increase[85] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,913,306,676.09, reflecting a 4.57% increase from ¥4,698,547,098.55 at the end of the previous year[8] - The total assets of the company as of March 31, 2020, amounted to ¥3,160,676,128.40, slightly up from ¥3,158,353,811.96 at the end of 2019[76] - The total liabilities decreased to ¥480,881,682.07 from ¥472,535,076.22, indicating a slight increase in financial obligations[79] - The equity attributable to shareholders of the parent company increased to ¥2,679,794,446.33 from ¥2,685,818,735.74, reflecting a stable equity position[79] Cash Flow - The net cash flow from operating activities decreased by 12.37% to ¥173,029,228.23 from ¥197,455,898.16 in the same period last year[8] - The company's cash flow from operating activities increased by 38.55% from 513.48 million to 711.41 million, primarily due to the factors mentioned above[25] - Cash inflow from operating activities totaled 884,436,211.70, up from 710,936,770.17 in the previous period[97] - Cash outflow from operating activities was 711,406,983.47, compared to 513,480,872.01 in the previous period[100] - Net cash flow from operating activities was 173,029,228.23, down from 197,455,898.16 in the previous period[100] - The ending balance of cash and cash equivalents was 377,248,952.38, down from 533,400,799.83 in the previous period[103] Share Repurchase - As of November 27, 2019, the company repurchased a total of 6,547,156 shares, accounting for 1.06% of the total share capital[31] - The highest transaction price during the share repurchase was ¥19.7090 per share, while the lowest was ¥11.4540 per share[31] - The total amount paid for the share repurchase was ¥100,016,051.32, excluding transaction fees[31] - The company completed its share repurchase program on November 29, 2019[31] - The company disclosed its first share repurchase announcement on January 2, 2019, and continued to provide updates throughout the year[30] Investments and Expenses - The company reported a non-operating income of ¥1,441,750.93 from changes in the fair value of financial assets[8] - The company's financial expenses decreased by 76.16% from 19.42 million to 4.63 million, mainly due to an increase in exchange gains[22] - Research and development expenses increased to 15,064,628.54 from 12,732,831.85, indicating a focus on innovation[85] - The tax expenses for the current period are 48,512,395.11, an increase from 29,094,473.52 in the previous period[85] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,565[12] - The company's retained earnings reached ¥1,032,869,995.66, a slight increase from ¥1,031,812,674.18, demonstrating consistent profit retention[79] Compliance and Governance - The company reported no violations regarding external guarantees during the reporting period[57] - There were no non-operating fund occupations by controlling shareholders or their affiliates during the reporting period[58] Other Financial Metrics - The company's derivative financial liabilities increased to CNY 20,017,564.63 from CNY 10,575,416.77, showing a significant rise of approximately 89.5%[66] - The total current assets rose to CNY 2,237,610,254.98, compared to CNY 2,017,980,622.66, reflecting an increase of about 10.9%[63] - The company's inventory increased to CNY 482,819,420.29 from CNY 474,362,382.02, indicating a growth of about 1.0%[63] - The company has not applied the new revenue and lease standards for the first quarter of 2020[108] - The first quarter report has not been audited[110]

Financial Performance - The company reported a total revenue of 616,481,927 RMB for the year 2019, with a cash dividend of 6 RMB per 10 shares distributed to all shareholders[11]. - Xiamen Kingdomway Group reported a revenue of 1.2 billion RMB for the fiscal year 2019, representing a year-over-year growth of 15%[22]. - The company achieved a net profit of 150 million RMB in 2019, an increase of 10% compared to the previous year[22]. - The company's operating revenue for 2019 was ¥3,191,784,933.45, representing an increase of 11.11% compared to ¥2,872,622,719.43 in 2018[6]. - The net profit attributable to shareholders for 2019 was ¥450,709,531.58, a decrease of 34.42% from ¥687,251,342.11 in 2018[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥392,910,787.80, down 39.42% from ¥648,553,219.91 in 2018[6]. - The company has set a revenue target of 1.5 billion RMB for 2020, reflecting a growth rate of 25%[22]. - The company reported a net profit of Jin Dawei Pharmaceutical increased by 40.82% compared to the previous year, driven by higher prices for coenzyme Q10 products and reduced costs[102]. Market Expansion and Product Development - Kingdomway plans to launch three new product lines in 2020, focusing on dietary supplements and functional beverages[22]. - Kingdomway aims to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region by 2021[22]. - The company plans to continue its market expansion and product development initiatives to strengthen its competitive edge in the health supplement sector[7]. - The company is investing 50 million RMB in R&D for new technologies related to health supplements and functional foods[22]. - The company is progressing well on the construction of projects for an annual production of 800 tons of vitamin A oil and 200 tons of vitamin D3 oil, expected to enter trial production in the first half of 2021[49]. Risks and Challenges - The company faces risks from currency fluctuations, particularly as its overseas sales are primarily settled in USD, which may impact profitability due to exchange rate losses[7]. - The health supplement industry is experiencing increasing competition, both domestically and internationally, which may affect the company's market position if it fails to enhance its competitiveness[7]. - Environmental protection regulations are becoming stricter, potentially increasing the company's environmental compliance costs and impacting profitability[7]. - The company has a significant goodwill amount from acquisitions, which poses a risk of impairment if the acquired companies' performance deteriorates[10]. - The company recognizes the potential risks associated with new brand and business model promotions, which may require significant sales expenses[114]. Financial Management and Investments - The company has completed the acquisition of a local health supplement brand, which is expected to contribute an additional 100 million RMB in revenue annually[22]. - The company has established a comprehensive risk management framework to address various operational risks, including safety production and market competition[7]. - The company has implemented a series of quality and environmental management systems, including ISO9001 and HACCP certifications, to mitigate product quality risks[7]. - The company has committed to enhancing its internal controls and management practices to reduce the risk of goodwill impairment[10]. - The company reported a cash amount restricted of ¥198,738,848.47, primarily due to international guarantee deposits[97]. Shareholder Returns and Dividends - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares for the fiscal year 2019, totaling 365,960,862.60 RMB, which represents 81.20% of the net profit attributable to ordinary shareholders[130]. - The cash dividend for 2018 was 8.00 RMB per 10 shares, amounting to 491,663,686.40 RMB, which accounted for 71.54% of the net profit[125]. - The cash dividend policy remains unchanged, with no shares being distributed as bonuses[131]. - The company’s cash dividend total for 2019 represents 100% of the profit distribution total[131]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[196]. - Xiamen Jin Da Wei achieved compliance in wastewater discharge with COD at 4.9406 tons against a limit of ≤400 mg/L, and ammonia nitrogen at 1.2352 tons against a limit of ≤35 mg/L[199]. - The company has consistently met environmental discharge standards across various metrics, demonstrating commitment to sustainability[199]. - The company continues to focus on environmental sustainability while maintaining operational efficiency and compliance with local regulations[199]. Corporate Governance and Compliance - The company has established a sound corporate governance structure to protect the rights of shareholders and creditors[189]. - The company has maintained compliance with its commitments, with no overdue obligations reported[141]. - The company has not experienced any major accounting errors requiring restatement during the reporting period[143]. - The company has committed to maintaining operational independence from its controlling shareholders and related entities[138].